164 related articles for article (PubMed ID: 17910672)
1. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
2. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.
Leiter U; Marghoob AA; Lasithiotakis K; Eigentler TK; Meier F; Meisner C; Garbe C
Melanoma Res; 2009 Feb; 19(1):50-7. PubMed ID: 19430406
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
Livingstone E; Krajewski C; Eigentler TK; Windemuth-Kieselbach C; Benson S; Elsenbruch S; Hauschild A; Rompel R; Meiss F; Mauerer A; Kähler KC; Dippel E; Möllenhoff K; Kilian K; Mohr P; Utikal J; Schadendorf D
Eur J Cancer; 2015 Mar; 51(5):653-67. PubMed ID: 25638778
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of skin cancer screening for individuals age 14 to 34 years.
Schmitt J; Seidler A; Heinisch G; Sebastian G
J Dtsch Dermatol Ges; 2011 Aug; 9(8):608-16. PubMed ID: 21501381
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
7. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
9. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
10. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
11. Follow-up in patients with localised primary cutaneous melanoma.
Francken AB; Bastiaannet E; Hoekstra HJ
Lancet Oncol; 2005 Aug; 6(8):608-21. PubMed ID: 16054572
[TBL] [Abstract][Full Text] [Related]
12. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.
Francken AB; Shaw HM; Accortt NA; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2007 Jun; 14(6):1924-33. PubMed ID: 17357855
[TBL] [Abstract][Full Text] [Related]
13. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study.
Podlipnik S; Carrera C; Sánchez M; Arguis P; Olondo ML; Vilana R; Rull R; Vidal-Sicart S; Vilalta A; Conill C; Malvehy J; Puig S
J Am Acad Dermatol; 2016 Sep; 75(3):516-524. PubMed ID: 27183845
[TBL] [Abstract][Full Text] [Related]
14. Economic Costs Avoided by Diagnosing Melanoma Six Months Earlier Justify >100 Benign Biopsies.
Aires DJ; Wick J; Shaath TS; Rajpara AN; Patel V; Badawi AH; Li C; Fraga GR; Doolittle G; Liu DY
J Drugs Dermatol; 2016 May; 15(5):527-32. PubMed ID: 27168261
[TBL] [Abstract][Full Text] [Related]
15. Skin-cancer screening: a three-year experience that paid for itself.
Limpert GH
J Fam Pract; 1995 May; 40(5):471-5. PubMed ID: 7730771
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
Dixon S; Walters SJ; Turner L; Hancock BW
Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of skin cancer prevention in Australia.
Shih ST; Carter R; Sinclair C; Mihalopoulos C; Vos T
Prev Med; 2009 Nov; 49(5):449-53. PubMed ID: 19747936
[TBL] [Abstract][Full Text] [Related]
19. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry.
Leiter U; Buettner PG; Eigentler TK; Bröcker EB; Voit C; Gollnick H; Marsch W; Wollina U; Meier F; Garbe C
J Am Acad Dermatol; 2012 Jan; 66(1):37-45. PubMed ID: 21700361
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
